Home » Stocks » Cyclerion Therapeutics

Cyclerion Therapeutics, Inc. (CYCN)

Stock Price: $2.50 USD -0.08 (-3.10%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
Pre-market: $2.54 +0.04 (1.60%) Oct 28, 4:20 AM

Stock Price Chart

Key Info

Market Cap 84.80M
Revenue (ttm) 4.64M
Net Income (ttm) -93.13M
Shares Out 33.92M
EPS (ttm) -3.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $2.50
Previous Close $2.58
Change ($) -0.08
Change (%) -3.10%
Day's Open 2.56
Day's Range 2.47 - 2.59
Day's Volume 768,851
52-Week Range 1.69 - 14.77

More Stats

Market Cap 84.80M
Enterprise Value 80.93M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 33.92M
Float 29.33M
EPS (basic) -3.38
EPS (diluted) -3.38
FCF / Share -3.29
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 937,901
Short Ratio 3.49
Short % of Float 3.20%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 18.27
PB Ratio 1.39
Revenue 4.64M
Operating Income -96.98M
Net Income -93.13M
Free Cash Flow -91.45M
Net Cash 3.87M
Net Cash / Share 0.11
Gross Margin 97.09%
Operating Margin -2,089.10%
Profit Margin -2,006.30%
FCF Margin -1,970.08%
ROA -31.28%
ROE -89.86%
ROIC -73.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $2.50
Target: 4.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit4.51---
Operating Income-125-115-93.92-63.55
Net Income-123-115-93.92-63.55
Shares Outstanding27.3827.38--
Earnings Per Share-4.49-4.21--
Operating Cash Flow-102-97.50-81.22-49.87
Capital Expenditures-6.72-3.44-1.40-1.45
Free Cash Flow-109-101-82.62-51.32
Cash & Equivalents94.90---
Total Debt73.92---
Net Cash / Debt20.98---
Book Value97.73-10.45-8.57-6.76
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cyclerion Therapeutics, Inc.
Country United States
Employees 94
CEO Peter M. Hecht

Stock Information

Ticker Symbol CYCN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CYCN


Cyclerion Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.